home / stock / alpmy / alpmy quote
Last: | $10.55 |
---|---|
Change Percent: | 1.25% |
Open: | $10.88 |
Close: | $10.42 |
High: | $10.88 |
Low: | $10.5 |
Volume: | 156,348 |
Last Trade Date Time: | 07/23/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$10.55 | $10.88 | $10.42 | $10.88 | $10.5 | 156,348 | 07-23-2024 |
$10.42 | $10.12 | $10.42 | $10.51 | $10.12 | 124,441 | 07-22-2024 |
$10.34 | $10.325 | $10.34 | $10.39 | $10.32 | 310,914 | 07-19-2024 |
$10.6024 | $10.71 | $10.6024 | $10.77 | $10.51 | 180,826 | 07-18-2024 |
$10.64 | $10.7 | $10.64 | $10.71 | $10.64 | 178,491 | 07-17-2024 |
$10.44 | $10.04 | $10.44 | $10.44 | $10.04 | 128,918 | 07-16-2024 |
$10.42 | $10.45 | $10.42 | $10.5 | $10.4 | 67,806 | 07-15-2024 |
$10.46 | $10.36 | $10.46 | $10.48 | $10.32 | 136,217 | 07-12-2024 |
$10.33 | $10.2 | $10.33 | $10.42 | $10.2 | 243,741 | 07-11-2024 |
$10.1 | $9.81 | $10.1 | $10.12 | $9.81 | 120,148 | 07-10-2024 |
$10.06 | $10.5099 | $10.06 | $10.5099 | $10.04 | 351,421 | 07-09-2024 |
$9.995 | $9.91 | $9.995 | $10.01 | $9.9 | 114,848 | 07-08-2024 |
$10.02 | $9.71 | $10.02 | $10.02 | $9.71 | 117,047 | 07-05-2024 |
$9.805 | $9.81 | $9.805 | $9.83 | $9.78 | 51,511 | 07-04-2024 |
$9.805 | $9.81 | $9.805 | $9.83 | $9.78 | 51,511 | 07-03-2024 |
$9.82 | $9.8 | $9.82 | $9.85 | $9.78 | 203,703 | 07-02-2024 |
$9.84 | $9.83 | $9.84 | $9.87 | $9.8 | 380,842 | 07-01-2024 |
$9.86 | $9.87 | $9.86 | $9.91 | $9.84 | 203,889 | 06-28-2024 |
$9.92 | $9.93 | $9.92 | $9.99 | $9.92 | 175,259 | 06-27-2024 |
$9.805 | $9.82 | $9.805 | $9.82 | $9.78 | 153,410 | 06-26-2024 |
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc. ADR Company Name:
ALPMY Stock Symbol:
OTCMKTS Market:
Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy PR Newswire - Collaborative Research on Innovative Cartilage Organoid Cell Therapy for In...
U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE PR Newswire If approved, the investigational therapy would offer a new treatment option for patients with advanced gastric and gastroesophageal junction canc...
Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies PR Newswire - Focuses on digitizing cell manufacturing processes through robotics technology TOKYO ,...